Published in Nature on April 29, 2010
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes | NCT00435981
Super-enhancers in the control of cell identity and disease. Cell (2013) 7.50
Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet (2011) 3.95
Type 1 diabetes. Lancet (2013) 3.45
Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab (2012) 2.39
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol (2013) 2.23
Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med (2015) 2.13
Dendritic cell control of tolerogenic responses. Immunol Rev (2011) 2.13
Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol (2012) 2.11
Metagenomics and personalized medicine. Cell (2011) 2.00
Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest (2012) 1.84
Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res (2014) 1.79
Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A (2011) 1.77
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
The glial glutamate transporter 1 (GLT1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell death. J Biol Chem (2011) 1.72
Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci U S A (2010) 1.66
Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov (2012) 1.63
IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54
The role of aging upon β cell turnover. J Clin Invest (2013) 1.50
Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care (2012) 1.49
Organ-specific features of natural killer cells. Nat Rev Immunol (2011) 1.48
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med (2012) 1.44
It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes (2011) 1.42
Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes (2011) 1.33
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 1.30
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia (2012) 1.29
The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. Diabetes (2012) 1.27
Genetics of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 1.25
Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease. Diabetes Care (2015) 1.25
Rituximab selectively suppresses specific islet antibodies. Diabetes (2011) 1.23
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care (2013) 1.21
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol (2011) 1.20
Immunological applications of stem cells in type 1 diabetes. Endocr Rev (2011) 1.20
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest (2015) 1.19
ER stress as a trigger for β-cell dysfunction and autoimmunity in type 1 diabetes. Diabetes (2012) 1.19
Bimodal effect on pancreatic β-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes (2011) 1.18
Soluble factors secreted by T cells promote β-cell proliferation. Diabetes (2013) 1.14
Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab (2013) 1.13
An update on the use of NOD mice to study autoimmune (Type 1) diabetes. Expert Rev Clin Immunol (2010) 1.13
Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig (2014) 1.09
Germline TRAV5D-4 T-cell receptor sequence targets a primary insulin peptide of NOD mice. Diabetes (2012) 1.09
T cell tolerance and immunity to commensal bacteria. Curr Opin Immunol (2012) 1.06
Gut microbiota, probiotics and diabetes. Nutr J (2014) 1.06
Body temperature regulation in diabetes. Temperature (Austin) (2016) 1.06
Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease. Diabetologia (2012) 1.04
Tissue-specific methylation of human insulin gene and PCR assay for monitoring beta cell death. PLoS One (2014) 1.02
Stem cell approaches for diabetes: towards beta cell replacement. Genome Med (2011) 1.02
Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes. J Biol Chem (2012) 1.02
Excessive Th1 responses due to the absence of TGF-β signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc Natl Acad Sci U S A (2013) 1.02
Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes. Cold Spring Harb Perspect Med (2012) 1.01
Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun (2012) 1.01
Virus infection, antiviral immunity, and autoimmunity. Immunol Rev (2013) 1.00
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
Can exposure to environmental chemicals increase the risk of diabetes type 1 development? Biomed Res Int (2015) 0.99
Protection against or triggering of Type 1 diabetes? Different roles for viral infections. Expert Rev Clin Immunol (2011) 0.99
Genome-wide analysis of copy number variation in type 1 diabetes. PLoS One (2010) 0.96
Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat Rev Endocrinol (2013) 0.96
Trends in Incidence Rates during 1999-2008 and Prevalence in 2008 of Childhood Type 1 Diabetes Mellitus in Germany--Model-Based National Estimates. PLoS One (2015) 0.95
Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire. J Biol Chem (2011) 0.94
Immune intervention in type 1 diabetes. Semin Immunol (2011) 0.94
Primary and secondary prevention of Type 1 diabetes. Diabet Med (2013) 0.94
Upregulation of phagocyte-like NADPH oxidase by cytokines in pancreatic beta-cells: attenuation of oxidative and nitrosative stress by 2-bromopalmitate. Biochem Pharmacol (2012) 0.93
Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy? Front Immunol (2012) 0.93
T cell-driven initiation and propagation of autoimmune diabetes. Curr Opin Immunol (2011) 0.92
The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model. J Immunol (2012) 0.92
Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech (2014) 0.92
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells. Elife (2014) 0.91
Juvenile Diabetes Research Foundation: mission, strategy, and priorities. Diabetes (2012) 0.90
Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin Dev Immunol (2011) 0.90
Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice. Nat Commun (2016) 0.89
Nonviral-mediated hepatic expression of IGF-I increases Treg levels and suppresses autoimmune diabetes in mice. Diabetes (2012) 0.89
Extrapancreatic autoantibody profiles in type I diabetes. PLoS One (2012) 0.88
Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) mice. J Biol Chem (2012) 0.88
Diabetes mellitus related bone metabolism and periodontal disease. Int J Oral Sci (2015) 0.88
Islet antigen-specific Th17 cells can induce TNF-α-dependent autoimmune diabetes. J Immunol (2014) 0.88
Antigen recognition in the islets changes with progression of autoimmune islet infiltration. J Immunol (2014) 0.87
2011 Update: antigen-specific therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes (2011) 0.87
Genome-wide transcriptional analyses of islet-specific CD4+ T cells identify Idd9 genes controlling diabetogenic T cell function. J Immunol (2015) 0.87
Microbial antigen mimics activate diabetogenic CD8 T cells in NOD mice. J Exp Med (2016) 0.87
The pancreatic β cell and type 1 diabetes: innocent bystander or active participant? Trends Endocrinol Metab (2013) 0.86
Induction of protective genes leads to islet survival and function. J Transplant (2011) 0.85
Oxysterol-EBI2 signaling in immune regulation and viral infection. Eur J Immunol (2014) 0.84
Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes (2013) 0.84
CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. J Leukoc Biol (2013) 0.84
The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes. Front Immunol (2012) 0.84
Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes (2012) 0.84
Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care (2013) 0.83
Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes. Rev Diabet Stud (2012) 0.83
SENP1-mediated NEMO deSUMOylation in adipocytes limits inflammatory responses and type-1 diabetes progression. Nat Commun (2015) 0.83
New and future immunomodulatory therapy in type 1 diabetes. Trends Mol Med (2012) 0.83
Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies. Diabetes (2012) 0.83
Diabetes imaging-quantitative assessment of islets of Langerhans distribution in murine pancreas using extended-focus optical coherence microscopy. Biomed Opt Express (2012) 0.83
Effects of crocin and zinc chloride on blood levels of zinc and metabolic and oxidative parameters in streptozotocin-induced diabetic rats. Avicenna J Phytomed (2015) 0.82
Type 1 diabetes and polyglandular autoimmune syndrome: A review. World J Diabetes (2015) 0.82
Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis. J Clin Invest (2015) 0.82
DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes. Diabetes (2015) 0.82
Reprogramming of various cell types to a beta-like state by Pdx1, Ngn3 and MafA. PLoS One (2013) 0.82
Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science (2009) 16.35
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med (2009) 9.71
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med (2001) 6.22
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med (2008) 5.74
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu (1980) 5.03
"Infectious" transplantation tolerance. Science (1993) 4.98
HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes (2008) 4.94
Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest (2009) 4.74
Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet (2008) 4.66
Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol (2009) 4.07
The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet (1997) 3.70
The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia (2009) 3.70
Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev (2008) 3.67
Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet (1997) 3.62
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Genetics of type 1A diabetes. N Engl J Med (2009) 3.18
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med (2003) 2.94
Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol (2009) 2.93
Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest (2007) 2.81
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest (1993) 2.64
B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol (1998) 2.63
Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest (2006) 2.58
Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57
The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol (2008) 2.39
T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity (2009) 2.34
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med (2002) 2.29
How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity (2009) 2.15
Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet (1986) 2.10
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA (2007) 2.04
Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia (2010) 2.04
B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol (2008) 1.96
Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab (2008) 1.91
The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A (2008) 1.85
Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A (2008) 1.83
Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes (2004) 1.76
Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73
A comprehensive guide to antibody and T-cell responses in type 1 diabetes. Tissue Antigens (2003) 1.71
Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity (1999) 1.69
On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes (2008) 1.61
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol (2010) 1.57
Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes (2005) 1.53
Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia (2005) 1.52
Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res (1985) 1.48
Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med (1988) 1.47
Extracellular redox modulation by regulatory T cells. Nat Chem Biol (2009) 1.45
Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J Clin Invest (2005) 1.42
Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetologia (2006) 1.41
Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A (2007) 1.35
Type 1 diabetes genes and pathways shared by humans and NOD mice. J Autoimmun (2005) 1.34
Editorial: Mortality and renal disease in type 1 diabetes mellitus--progress made, more to be done. J Clin Endocrinol Metab (2006) 1.29
How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol (1998) 1.29
TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol (2007) 1.21
Long-term risk of IDDM in first-degree relatives of patients with IDDM. Diabetologia (1994) 1.20
Interferon-alpha as a mediator of polyinosinic:polycytidylic acid-induced type 1 diabetes. Diabetes (2005) 1.18
AIRE in the thymus and beyond. Curr Opin Immunol (2009) 1.16
T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol (2009) 1.16
The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice. Immunol Rev (2005) 1.13
Conserved T cell receptor alpha-chain induces insulin autoantibodies. Proc Natl Acad Sci U S A (2008) 1.10
In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression. Magn Reson Med (2008) 1.04
Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care (1999) 1.00
BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J Autoimmun (1997) 0.98
The BB/Wor rat and the balance hypothesis of autoimmunity. Diabetes Metab Rev (1996) 0.98
Type 1 diabetes environmental factors and correspondence analysis of HLA class II genes in the Yemenite Jewish community in Israel. Diabetes Care (2001) 0.97
Analysis of mortality in French diabetic patients from death certificates: a comparative study. Diabetes Metab (1999) 0.97
Cytokine related therapies for autoimmune disease. Curr Opin Immunol (2008) 0.92
Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials. Diabetol Metab Syndr (2009) 0.86
CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts. Eur J Immunol (1999) 0.83
International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43
Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes (2010) 2.94
Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2009) 2.91
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet (2008) 2.27
Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol (2007) 2.04
Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev (2012) 1.68
Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci U S A (2011) 1.68
Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol (2006) 1.67
Identification of tissue-restricted transcripts in human islets. Endocrinology (2004) 1.63
Expansion and redifferentiation of adult human pancreatic islet cells. Biochem Biophys Res Commun (2006) 1.60
Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clin Trials (2010) 1.33
Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol (2007) 1.26
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care (2013) 1.23
Rituximab selectively suppresses specific islet antibodies. Diabetes (2011) 1.23
Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci (2008) 1.17
Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med (2007) 1.15
Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes Care (2009) 1.14
Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol (2008) 1.07
Insulin autoimmunity and hypoglycemia in seven white patients. Endocr Pract (2005) 1.02
Increasing problem solving in adolescents with type 1 diabetes: the choices diabetes program. Diabetes Educ (2002) 1.01
Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci (2005) 1.01
The second murine autoantibody workshop: remarkable interlaboratory concordance for radiobinding assays to identify insulin autoantibodies in nonobese diabetic mice. Ann N Y Acad Sci (2003) 0.98
Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLoS One (2013) 0.97
Following the fate of one insulin-reactive CD4 T cell: conversion into Teffs and Tregs in the periphery controls diabetes in NOD mice. Diabetes (2012) 0.96
Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility. J Immunol Methods (2009) 0.91
Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes (2010) 0.89
Development of new-generation HU-PBMC-NOD/SCID mice to study human islet alloreactivity. Ann N Y Acad Sci (2007) 0.87
Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care (2014) 0.86
A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care (2011) 0.84
Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing. Endocrinol Metab Clin North Am (2006) 0.81
IFIH1 gene polymorphisms in type 1 diabetes: genetic association analysis and genotype-phenotype correlation in Chinese Han population. Autoimmunity (2011) 0.80
International Workshop on Lessons from Animal Models for Human Type 1 Diabetes: analyzing target autoantigens of humoral immunity in nonobese diabetic mice. Ann N Y Acad Sci (2002) 0.80
Early over expression of messenger RNA for multiple genes, including insulin, in the Pancreatic Lymph Nodes of NOD mice is associated with Islet Autoimmunity. BMC Med Genomics (2009) 0.79
The ligand/RAGE axis: lighting the fuse and igniting vascular stress. Curr Atheroscler Rep (2006) 0.79
Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes. J Immunol (2012) 0.79
Absence of the T-bet gene coding for the Th1-related transcription factor does not affect diabetes-associated phenotypes in Balb/c mice. Ann N Y Acad Sci (2003) 0.78
RAGE: exacting a toll on the host in response to polymicrobial sepsis and Listeria monocytogenes. Crit Care (2007) 0.78
Comparative study of oral versus subcutaneous B:9-23 insulin peptide in Balb/c mice as an experimental model for autoimmune diabetes. Ann N Y Acad Sci (2004) 0.77
Translating mucosal antigen based prevention of autoimmune diabetes to human. Novartis Found Symp (2008) 0.76
Genetic determinants of 21-hydroxylase autoantibodies amongst patients of the Type 1 Diabetes Genetics Consortium. J Clin Endocrinol Metab (2012) 0.76
Discordant association of islet autoantibodies with high-risk HLA genes in Chinese type 1 diabetes. Diabetes Metab Res Rev (2011) 0.75
MICA gene polymorphism in HBDI multiplex families. Ann N Y Acad Sci (2004) 0.75
Yale Center for Clinical Investigation: leveraging industry partnerships and research cores. Clin Transl Sci (2012) 0.75